Efficacy of Zoledronic Acid in Osteoporosis

Examination of Bone Metabolism and Bone Mineral Density by Zoledronic Acid in Primary and Secondary Osteoporosis

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03183557

Enrollment

100

Registered

2017-06-12

Start date

2017-10-12

Completion date

2025-06-08

Last updated

2021-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Brief summary

There has been no comparative data between Zoledronic acid and Zoledronic acid combined with active vitamin D in primary and secondary osteoporosis.

Interventions

DRUGZoledronic acid, Reclast®

To examine the efficacy of zoledronic acid in osteoporosis

DRUGZoledronic acid, Reclast® and active vitamin D, alfacalcidol®

To examine the efficacy of zoledronic acid plus alfacalcidol in osteoporosis

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Osteoporotic patients who want to take zoledronic acid

Exclusion criteria

* Patients who are allergic to zoledronic acid or vitamin D * Patients who are pregnant or breast-feeding * Patients who have not taken zoledronic acid for the last 2 years

Design outcomes

Primary

Measure	Time frame
Bone mineral density	Change from Baseline Values at 1 year

Countries

Japan

Contacts

Primary ContactYukio Nakamura, MD, PhD

yxn14@aol.jp+81-263-37-2659

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026